Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide + LPV/r in HIV-1 patients failing first-line ART
NCT02369965Phase 3Completed
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Feb 2014
- Primary completion
- Apr 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of albuvirtide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Frontier Biotechnologies Inc.. Started Feb 2014; status: completed.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02369965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369965.